DGAP-News: HAEMATO AG: Results Q1 2020
DGAP-News: HAEMATO AG
/ Key word(s): Quarter Results/Quarterly / Interim Statement
HAEMATO AG Corporate News: HAEMATO AG, Berlin (ISIN: DE0006190705), achieved IFRS consolidated sales of EUR 197.8 million (previous year: EUR 274.1 million), an operating profit (EBIT) of EUR -19 thousand (previous year: EUR 6.6 million) and an annual profit of EUR -1.17 million (previous year: EUR 6.3 million). The annual report is available for download on our corporate website at https://haemato.ag/en/investor-relations/publications. In the first quarter of 2020, HAEMATO AG generated IFRS consolidated sales of EUR 60.6 million and EBITDA of EUR 954 thousand (previous year: EUR 1,360 thousand). The turnover was thus 25.3% above the sales volume in the equivalent revious-year period, which totalled EUR 48.4 million in the first quarter of 2019. The adjustment of the product portfolio in the first quarter of 2020 had a negative impact on the gross margin. In the first quarter 2020, we were able to market 38 approvals for new products and thus restructure our product portfolio. As one of the leading providers of specialty pharmaceuticals, the HAEMATO Group benefits from competition in the primary healthcare market. The specialization in medicines for the treatment of chronic diseases and for individual therapies leads us to expect a potential for growth in the future due to demographic development. About HAEMATO: HAEMATO AG, founded in 1993, is a pharmaceutical company focusing on the growing markets of high-priced specialty pharmaceuticals in the indication areas of oncology and HIV as well as other chronic diseases. HAEMATO AG is listed in the Basic Board (Open Market) of the Frankfurt Stock Exchange. Contact: HAEMATO AG, Investor Relations Telefon: +49 (0)30 897 30 86 70 [email protected]
18.05.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
Language: | English |
Company: | HAEMATO AG |
Lilienthalstraße 5c | |
12529 Schönefeld | |
Germany | |
Phone: | +49 (0)30 897 30 86 70 |
Fax: | +49 (0)30 897 30 86 79 |
E-mail: | [email protected] |
Internet: | www.haemato.ag |
ISIN: | DE0006190705 |
WKN: | 619070 |
Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Stuttgart, Tradegate Exchange |
EQS News ID: | 1049989 |
End of News | DGAP News Service |
|
1049989 18.05.2020